Levetiracetam (All indications)

Caesarean

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9001
R30572		 Koc (Levetiracetam), 2018 Cesarean during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 1.88 [0.67;5.29] C 17/28   14/31 31 28
ref
S8983
R30479		 Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.32 [0.34;5.08] C
excluded (control group) 		3/13   32/173 35 13
ref
S8984
R30491		 Artama (Levetiracetam) (Controls unexposed, disease free), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.49 [0.41;5.48]
excluded (control group) 		3/13   114,791/721,948 114,794 13
ref
S8985
R30503		 Artama (Levetiracetam) (Controls unexposed, sick), 2013 Caesarean section during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.05 [0.28;3.96] 3/13   331/1,800 334 13
ref
Total 2 studies 1.50 [0.67;3.41] 365 41
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Koc (Levetiracetam), 2018Koc, 2018 1 1.88[0.67; 5.29]312862%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Artama (Levetiracetam) (Controls unexposed, sick), 2013Artama, 2013 2 1.05[0.28; 3.96]3341338%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.50[0.67; 3.41]365410.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam; 2: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.50[0.67; 3.41]365410%NAKoc (Levetiracetam), 2018 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.50[0.67; 3.41]365410%NAKoc (Levetiracetam), 2018 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 Tags Adjustment   - No  - No 1.88[0.67; 5.29]3128 -NAKoc (Levetiracetam), 2018 1   - Yes  - Yes 1.05[0.28; 3.95]33413 -NAArtama (Levetiracetam) (Controls unexposed, sick), 2013 1 All studiesAll studies 1.50[0.67; 3.41]365410%NAKoc (Levetiracetam), 2018 Artama (Levetiracetam) (Controls unexposed, sick), 2013 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8983, 8984

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.49[0.41; 5.45]114,79413 -NAArtama (Levetiracetam) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 1.50[0.67; 3.41]365410%NAKoc (Levetiracetam), 2018 Artama (Levetiracetam) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.32[0.34; 5.08]3513 -NAArtama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 10.510.01.0